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Overexpression of SGTP and/or MT may contribute to various carcinogenic pro-
cesses and to resistance to anticancer treatment. The importance of these pro-
teins, although clearly established in solid tumours, has not been fully under-
stood in haematopoietic neoplasm. The aim of this study was to determine the
expression of MT and SGTP in the bone marrow of patients with MPD. Twenty
paraffin-embedded bone marrow core biopsy specimens from newly diagnosed
patients with MPD were evaluated — osteomyelofibrosis (OMF), n = 9 and
chronic myelocytic leukaemia (CML), n = 11. We demonstrate increased SGTP
and MT expression in the bone marrow of MPD patients. In our study levels of
MT in OMF patients were higher than in CML. This suggests that MT expression
may correlate with bone marrow fibrosis. These data, although based on a rela-
tively small number of patients, raise the possibility that SGTP and MT may play
a role in the pathogenesis of MPD. The clinical significance of this phenomenon
needs further investigation.
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INTRODUCTION
Metallothionein (MT) is low molecular weight
cysteine-rich protein, which has the ability to bind
and sequestrate heavy metal ions such as zinc, cop-
per, cadmium and mercury. MT plays an important
role in the detoxification of toxic metals and proba-
bly in cellular protection against ionising radiation
and cytotoxic drugs [9]. Gluthatione s-transferase pi
(SGTP) belongs to a family of detoxification enzymes.
Malignant tumours often contain increased amounts
of SGTP [10]. Myeloproliferative disorders (MPD) are
clonal diseases originating in a pluripotential hae-
matopoietic stem cell. MPD are characterised by
abnormally high levels of cells of particular haemato-
poietic cell lineage. The clinical course and manage-
ment differ among the various disorders. MPD in-
clude chronic myelogenous leukaemia (CML), poly-
cythaemia vera (PV), essential thrombocythaemia
(ET), and myelofibrosis with myeloid metaplasia
(OMF) [3, 7].
MT and SGTP overexpression has been found in
various solid tumours [1, 4, 5, 10]. There are limited
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data concerning the role of MT and SGTP in haema-
tological malignancies. The aim of this study was to
determine the expression of MT and SGTP in the bone
marrow of patients with MPD.
MATERIAL AND METHODS
20 paraffin-embedded bone marrow core biop-
sy specimens from patients newly diagnosed with
MPD were evaluated — osteomyelofibrosis (OMF),
n = 9 and chronic myelocytic leukaemia in the chron-
ic phase (CML), n = 11. The OMF was diagnosed ac-
cording to Polycytaemia Vera Study Group criteria.
The diagnosis of CML was confirmed by the presence
of the Philadelphia chromosome and/or BCR-ABL on-
cogene [3, 7].
Bone marrow sections were stained immuno-
histochemically for MT and SGTP. The samples
under examination were fixed in 10% buffered
formalin and then embedded in paraffin. The prep-
arations were stained with haematoxylin and eosin
and evaluated histopathologically. The deparaffi-
nised sections were incubated with mouse mono-
clonal antibodies against MT and SGTP (Dako,
Denmark). At the next step streptavidin-biotiny-
lated peroxidase (LSAB2, Dako, Denmark) complex
was used and the activity of the latter was evalu-
ated using DAB (Dako, Denmark). In each case the
negative control was included with Primary Nega-
tive Control (Dako, Denmark) and then — LSAB2
and DAB.
RESULTS AND DISCUSSION
The results of SGTP and MT expression are sum-
marised in Figures 1 and 2.
Overexpression of SGTP and/or MT may contri-
bute to various carcinogenic processes and to re-
sistance to anticancer treatment. The importance
of these proteins, although clearly established in
solid tumours, has not been fully understood in hae-
matopoietic neoplasms. In acute myelocytic leu-
kaemias the gene encoding SGTP is up-regulated
[2]. MT and SGTP are involved in the resistance
mechanism in acute leukaemias [6]. There are sev-
eral reports that dysfunction of SGTP and impaired
function of the mechanisms of detoxification of en-
vironmental or endogenous carcinogens may in-
crease susceptibility to myelodysplastic syndromes
[8]. Enhanced expression of MT in cells induces an
antiapoptotic effect. [9].
CML and OMF are myeloproliferative disorders
resistant to standard chemotherapy. Treatment of
MPD is mainly directed towards palliation. The only
curative option for younger patients with CML and
OMF is allogeneic bone marrow transplantation. We
demonstrate increased SGTP and MT expression in
the bone marrow of MPD patients. There is evidence
that levels of MT are increased in proliferating cells
and differing fibroblasts [9]. Of the myeloprolifera-
tive disorders in OMF extremely pronounced bone
marrow stromal fibroblast proliferation is observed.
In our study levels of MT in OMF patients were high-
er than in those with CML. This suggests that MT
expression may correlate with bone marrow fibro-
sis. These data, although based on a relatively small
number of patients, raise the possibility that SGTP
and MT may play a role in the pathogenesis of MPD.
The clinical significance of this phenomenon needs
further investigation.
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